Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

PBB and PolyTherics Progress and Expand their Relationship

Published: Wednesday, November 21, 2012
Last Updated: Wednesday, November 21, 2012
Bookmark and Share
Development of improved blood factors.

Pro Bono Bio Group plc and PolyTherics Limited have announced progress on their haematology alliance to produce longer-acting versions of blood factor proteins.

The lead programme, for the development of TheraPEG™ Factor IX, has shown good technical and scientific progress and the parties have extended their agreement to actively pursue the development of a further blood factor product, TheraPEG™ Factor VIIa.

In addition, encouraged by the results achieved with these two programmes they have embarked on a feasibility study to assess the potential of a TheraPEG™ Factor VIII product.

PBB affiliates and PolyTherics have been working together to develop a longer-acting version of Factor IX using PolyTherics’ TheraPEG™ technology to conjugate poly(ethylene) glycol (“PEG”) to the protein.

PBB successfully completed a preclinical pharmacology study with TheraPEG™ Factor IX in 2011 and PolyTherics has now transferred its TheraPEG™ PEGylation process for this protein to PBB’s biomanufacturing affiliate to enable the production of larger quantities of this longer-acting blood factor for further development.

Completion of the technology transfer process triggered a milestone payment to PolyTherics in April 2012.

The Parties have also recently signed an exclusive global license agreement to develop and commercialize a PEGylated version of blood factor VIIa, which again uses the PolyTherics’ site-specific TheraPEG™ conjugation technology.

This product has successfully completed preclinical pharmacology studies and the TheraPEG™ PEGylation process is now being transferred to enable PBB’s biomanufacturing affiliate to produce material for further development.

PolyTherics is due to receive further development and regulatory milestones as well as royalties on future worldwide product sales under the terms of the TheraPEG™ license agreements for Factor IX and Factor VIIa. Clinical development of both products is expected to be initiated within the next 18-24 months.

In addition to the two license agreements, the Parties have signed an exclusive option agreement to develop a PEGylated form of blood factor VIII under a feasibility programme.

The option agreement includes a pre-agreed exclusive global license for TheraPEG™ Factor VIII.

John Mayo, CEO of PBB commented, “Pro Bono Bio has invested heavily in haematology and this partnership, together with our own internal development activity, is now bearing fruit. We are now confident of producing new products with life-changing benefits for haemophiliacs all over the world.”

John Burt, CEO of PolyTherics commented, “Progression of both TheraPEG™ Factor VIIa and TheraPEG™ Factor IX towards the clinic is an exciting development for PolyTherics and completion of the technology transfer reinforces our confidence in TheraPEG™ as an approach to enable the development of better biopharmaceuticals. We work flexibly with companies so that key stages of their programmes, such as technology transfer, can be built into agreements at the point which best suits our partners’ own resources and development strategy”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Designing Better Drugs
A rational drug engineering approach could breathe new life into drug development.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
New Model to Enhance Zika Virus Research
The model will allow researchers to better understand how the virus causes disease and aid in the development of antiviral compounds and vaccines.
Improving Flu Vaccine Effectiveness
NIH study finds factors that may influence influenza vaccine effectiveness.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
CNS Inflammation: A Pathway and Possible Drug Target
Scientists have long known that the central nervous system (CNS) has a remarkable ability to limit excessive inflammation in the presence of antigens or injury, but how it works has been unclear.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!